2026. IN-VITRO EFFICACY OF PIPERACILLIN/SULBACTAM AGAINST MULTIDRUG-RESISTANT PSEUDOMONAS AERUGINOSA: A COMPARATIVE STUDY WITH PIPERACILLIN/TAZOBACTAM AND CEFOPERAZONE/SULBACTAM. Frontier in Medical and Health Research. 4, 3 (Mar. 2026), 4971–4977.